Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Explore this paper's citation graph
Summary
It is suggested that endogenous tPA concentrations increase as a consequence of important preclinical atherosclerosis and therefore may be a marker for risk of future myocardial infarction.
- Type
- article
- Published
- 1993-05-08
- Cited by
- 640
- References
- 21
- OpenAlex
- https://openalex.org/W2076500453
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:20771877
Keywords
Medicine, Myocardial infarction, Internal medicine, Tissue plasminogen activator, T-plasminogen activator
References
- Plasminogen activator inhibitors.
- Impaired fibrinolysis and risk of thromboembolism.
- Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
- Plasma tissue plasminogen activator levels in patients with coronary heart disease.
- Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.
- Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor
- Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
- Disordered "fibrinolytic potential" in coronary heart disease.
- An epidemiologic assessment of thrombotic risk factors for cardiovascular disease
- A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
- Hemostatic risk factors for coronary heart disease.
- Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
- Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
- Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay.
- Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
- Epidemiologic issues in the design and use of biologic specimen banks.
- [Type 1 plasminogen activator inhibitor].
- Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
- Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
- Plasminogen activator inhibitors
Cited by
- A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION: DOES IT EXIST?
- Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity.
- Elevated Levels of Plasma C-Reactive Protein Are Associated With Decreased Graft Survival in Cardiac Transplant Recipients
- Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease
- Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
- Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction.
- Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease
- Cerebral Small Vessel Disease
- Pathogenesis and Pathology of Coronary Heart Disease Syndromes
- Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.
- Fibrinolysis/Proteolysis Balance in Stable Angina Pectoris in Relation to Angiographic Findings
- Plasmin Activation System in Restenosis: Role in Pathogenesis and Clinical Prediction?
- Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.
- Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability.
- Key References: Basic Fibrinolysis and Thrombolysis Selected References: 1987–1997
- Plasminogen activator inhibitor 1: Molecular aspects and clinical importance
- Hormone Replacement Therapy, Selective Estrogen Receptor Modulators, and Tissue-Specific Compounds
- Haemostasis and cardiovascular disease
- Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism
- PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events
Related papers
- Relative risk of mortality in the physically inactive is underestimated because of real changes in exposure level during follow-up.
- Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.
- Correlations between fibrinolytic function and acute myocardial infarction.
- The Association between Tea Consumption and the Risk of Fracture: A Dose—Response Meta-Analysis of Prospective Cohort Studies
- A Specific Immunologic Assay for Functional Plasminogen Activator Inhibitor 1 in Plasma – Standardized Measurements of the Inhibitor and Related Parameters in Patients with Venous Thromboembolic Disease
- Comparison of Tissue Plasminogen Activator (t-PA), Plasminogen Activator Inhibitor 1 (PAI-1) and t-PA·PAI-1 Complex Levels in Plasma and Serum Samples Obtained by Different Methods
- Advances in the Study of Tissue-type Plasminogen Activator and Its Toxicity in the Central Nervous System
- Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.